Latest News and Press Releases
Want to stay updated on the latest news?
-
VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference
BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
-
BRIDGEWATER, N.J., June 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
-
BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
-
Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to...
-
BRIDGEWATER, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
-
BRIDGEWATER, N.J., May 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
-
At week 2, FMX114 demonstrated a statistically significant reduction in both absolute and percent change in ADSI score compared to vehiclePhase 2a safety and efficacy results expected in the second...
-
VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg dosesVYN201 also demonstrated numerically superior results at 1mg/kg and...
-
FMX114 demonstrated preliminary clinical safety and pharmacokinetics in Phase 1b study VYN201 shows promising preclinical data in 3 well-established and validated inflammation models BRIDGEWATER,...
-
VYN201 0.1% and 1% resulted in statistically significant improvement in reducing both melanocyte loss and key inflammatory biomarkers involved in the pathogenesis of vitiligo, an immune-modulated skin...